Eli Lilly and Company (NYSE:LLY) Shares Bought by Compass Ion Advisors LLC

Compass Ion Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.3% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,340 shares of the company’s stock after purchasing an additional 117 shares during the period. Compass Ion Advisors LLC’s holdings in Eli Lilly and Company were worth $1,821,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LLY. Lipe & Dalton purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $26,000. Tidemark LLC acquired a new stake in Eli Lilly and Company during the fourth quarter valued at $29,000. Core Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares in the last quarter. Frank Rimerman Advisors LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at $37,000. Finally, St. Johns Investment Management Company LLC raised its position in shares of Eli Lilly and Company by 123.3% in the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after acquiring an additional 37 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 1,441 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the completion of the transaction, the insider now directly owns 97,367,369 shares in the company, valued at approximately $89,093,089,982.38. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 1,441 shares of the company’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $915.02, for a total value of $1,318,543.82. Following the transaction, the insider now owns 97,367,369 shares in the company, valued at $89,093,089,982.38. The disclosure for this sale can be found here. Insiders sold a total of 791,145 shares of company stock valued at $673,704,508 over the last quarter. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Up 1.0 %

NYSE LLY opened at $914.37 on Tuesday. The business’s fifty day simple moving average is $814.40 and its 200-day simple moving average is $740.86. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a market cap of $869.03 billion, a PE ratio of 134.66, a P/E/G ratio of 1.97 and a beta of 0.41. Eli Lilly and Company has a 52 week low of $434.34 and a 52 week high of $916.83.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the firm earned $1.62 earnings per share. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.57%. Eli Lilly and Company’s payout ratio is 76.58%.

Analysts Set New Price Targets

Several brokerages recently weighed in on LLY. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Jefferies Financial Group upped their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Finally, Citigroup lifted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $812.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.